Cost of Revenue Comparison: Teva Pharmaceutical Industries Limited vs Bausch Health Companies Inc.

Teva vs. Bausch: A Decade of Cost Dynamics

__timestampBausch Health Companies Inc.Teva Pharmaceutical Industries Limited
Wednesday, January 1, 201422546000009216000000
Thursday, January 1, 201526450000008296000000
Friday, January 1, 2016261100000010044000000
Sunday, January 1, 2017254800000011560000000
Monday, January 1, 2018235100000010558000000
Tuesday, January 1, 201923500000009351000000
Wednesday, January 1, 202022490000008933000000
Friday, January 1, 202123940000008284000000
Saturday, January 1, 202223640000007952000000
Sunday, January 1, 202325590000008200000000
Monday, January 1, 20248480000000
Loading chart...

Infusing magic into the data realm

Cost of Revenue: A Tale of Two Pharmaceutical Giants

In the competitive landscape of pharmaceuticals, Teva Pharmaceutical Industries Limited and Bausch Health Companies Inc. have been pivotal players. From 2014 to 2023, these companies have shown contrasting trends in their cost of revenue. Teva's cost of revenue peaked in 2017, reaching nearly 11.6 billion, but has since declined by approximately 30% to 8.2 billion in 2023. In contrast, Bausch Health's cost of revenue has remained relatively stable, fluctuating around the 2.4 billion mark, with a slight increase of about 14% from 2014 to 2023. This divergence highlights Teva's strategic shifts and cost management challenges, while Bausch Health maintains a steady course. As the pharmaceutical industry evolves, these trends offer insights into the operational efficiencies and market strategies of these two giants.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025